Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda (Q38861345)

7 September 2017

title

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda (English)

1 reference

7 September 2017

0 references

1 reference

1 reference

Aloysius Ssemaganda

5

0 references

Ligia A. Pinto

series ordinal

8

object named as

Ligia A Pinto

1 reference

7 September 2017

4

Edward Kumakech

1 reference

7 September 2017

7

Jane Cover

1 reference

7 September 2017

2

Emmanuel Mugisha

1 reference

7 September 2017

1

D Scott LaMontagne

1 reference

7 September 2017

Yuanji Pan

3

1 reference

7 September 2017

Troy J Kemp

series ordinal

6

1 reference

7 September 2017

Mahboobeh Safaeian

series ordinal

9

1 reference

7 September 2017

language of work or name

English

0 references

publication date

16 September 2014

1 reference

7 September 2017

1 reference

7 September 2017

volume

32

1 reference

7 September 2017

issue

47

1 reference

7 September 2017

page(s)

6303-6311

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Cervical cancer screening in the United States and the Netherlands: a tale of two countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Recommendations for cervical cancer prevention in sub-saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Human papillomavirus vaccine introduction--the first five years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Achieving high coverage in Rwanda's national human papillomavirus vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Assessment of eight HPV vaccination programs implemented in lowest income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

'It's a logistical nightmare!' Recommendations for optimising human papillomavirus school-based vaccination experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

High uptake of Gardasil vaccine among 9 - 12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

HPV infections in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.071

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.08.071

1 reference

7 September 2017

1 reference